The most common conditions

Title Effect Research Type Journal Year
Antipsychotic profile of cannabidiol and rimonabant in an animal model of emotional context processing in schizophrenia. positive animals Current pharmaceutical design 2012
Performance of schizophrenic patients in the Stroop Color Word Test and electrodermal responsiveness after acute administration of cannabidiol (CBD). NONE humans Revista brasileira de psiquiatria (Sao Paulo, Brazil : 1999) 2010
A behavioural comparison of acute and chronic Delta9-tetrahydrocannabinol and cannabidiol in C57BL/6JArc mice. positive animals The international journal of neuropsychopharmacology 2010
Effects of acute oral Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers. NONE humans European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2008
Improved Social Interaction, Recognition and Working Memory with Cannabidiol Treatment in a Prenatal Infection (poly I:C) Rat Model. positive animals Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2017
Cannabidiol Counteracts Amphetamine-Induced Neuronal and Behavioral Sensitization of the Mesolimbic Dopamine Pathway through a Novel mTOR/p70S6 Kinase Signaling Pathway. positive animals The Journal of neuroscience : the official journal of the Society for Neuroscience 2016
Effects of cannabinoid drugs on the deficit of prepulse inhibition of startle in an animal model of schizophrenia: the SHR strain. positive animals Frontiers in pharmacology 2014
Title Effect Research Type Journal Year
The phytocannabinoid, Δ⁹-tetrahydrocannabivarin, can act through 5-HT₁A receptors to produce antipsychotic effects. positive animals British journal of pharmacology 2015
Title Effect Research Type Journal Year
Novel molecular changes induced by Nrg1 hypomorphism and Nrg1-cannabinoid interaction in adolescence: a hippocampal proteomic study in mice. NONE animals Frontiers in cellular neuroscience 2013
Synthetic delta-9-tetrahydrocannabinol elicits schizophrenia-like negative symptoms which are distinct from sedation. negative humans Human psychopharmacology 2011
The safety of studies with intravenous Δ⁹-tetrahydrocannabinol in humans, with case histories. SAFE humans Psychopharmacology 2012
Involvement of the endocannabinoid system in phencyclidine-induced cognitive deficits modelling schizophrenia. negative animals The international journal of neuropsychopharmacology 2009
Effects of acute oral Delta9-tetrahydrocannabinol and standardized cannabis extract on the auditory P300 event-related potential in healthy volunteers. NONE humans European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2008
The Differential Binding of Antipsychotic Drugs to the ABC Transporter P-Glycoprotein Predicts Cannabinoid-Antipsychotic Drug Interactions. negative animals Neuropsychopharmacology : official publication of the American College of Neuropsychopharmacology 2017
Delta-9-tetrahydrocannabinol effects in schizophrenia: implications for cognition, psychosis, and addiction. NONE humans Biological psychiatry 2005
THC and endocannabinoids differentially regulate neuronal activity in the prefrontal cortex and hippocampus in the subchronic PCP model of schizophrenia. NONE animals Journal of psychopharmacology (Oxford, England) 2016
Repeated but not acute treatment with ∆⁹-tetrahydrocannabinol disrupts prepulse inhibition of the acoustic startle: reversal by the dopamine D₂/₃ receptor antagonist haloperidol. negative animals European neuropsychopharmacology : the journal of the European College of Neuropsychopharmacology 2014